ClinicalTrials.gg
CompletedNCT06840925Updated Aug 3, 2026

A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628

A Phase 1 interventional study of PRAX-628 in Healthy, sponsored by Praxis Precision Medicines. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Praxis Precision Medicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A phase I clinical trial to evaluate the relative bioavailability of PRAX-628 tablet formulation compared to capsule formulation

Read the detailed description

This Phase 1, randomized, open-label, 2-way crossover clinical trial is designed to investigate the relative bioavailability, pharmacokinetics (PK), safety, and tolerability of PRAX628 tablet formulation and PRAX-628 capsule formulation in healthy male or female participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Praxis Precision Medicines is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight of at least 50 kg with (BMI) between 18 and 32 kg/m2
  • Is in good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations
  • All females have a negative pregnancy test and are not planning to get pregnant for the duration of the trial
  • Female of non- by reason of surgery or at least 1 year post menopause
  • Additional inclusion criteria apply and will be assessed by the study team

Exclusion criteria

Exclusion Criteria:

  • Any abnormalities, medical, or psychiatric conditions identified by a detailed medical history, or physical examination
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs. Examples of such conditions include (but are not limited to):

    1. History of inflammatory bowel syndrome, gastritis, gastrointestinal or rectal bleeding
    2. History of major gastrointestinal tract surgery (ie, gastrectomy, bowel resection, cholecystectomy etc.)
    3. History or evidence of pancreatic injury or pancreatitis
  • History or presence of impaired renal function supported by estimated [eGFR]\<60 mL/min/1.73m2 or clinically significant abnormal urinary constituents (eg, protein)
  • History of cancer except for nonmelanoma skin cancer resected >2 years ago and that has been definitively treated and considered cured.
  • History of any lifetime suicide attempt or active suicidal ideation with intent as indicated by a "Yes" response to either Question 4 or 5 on the C-SSRS "Baseline/ Screening" version
  • History of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short syndrome, or family (first degree relative) history of sudden death, ventricular or clinically significant arrhythmias, including idiopathic ventricular fibrillation.
  • Abnormal standard 12-lead after at least 5 minutes resting in the supine position
  • Abnormal vital signs after at least 5 minutes resting in the supine position:
  • Has any of the following: a serum total value >1.1× the (ULN), a serum (ALT) value >1.5×ULN, or aspartate aminotransferase (AST) value >1.5×ULN
  • Serology test positive for (HIV), or or C
  • Known allergy or to any component of the formulation of PRAX 628 or history of severe allergy or anaphylaxis to a drug, food, or other exposure
  • Use of any experimental or drug or device within 30 days prior to the first dose of study drug or 5 times the terminal half-life of the drug, whichever is longer
  • Use of systemic prescription medications; or over-the-counter medication, including multivitamins; and dietary and herbal supplements within 2 weeks or 5 times the terminal half-life of the medication prior to the first dose of study drug (whichever is longer) and for the duration of the trial
  • Donation of blood within 1 month prior to Screening, plasma within 1 week prior to Screening, or within 6 weeks prior to Screening
  • Any vaccination within 28 days of the first dose of study drug
  • Additional exclusion criteria apply and will be assessed by the study team
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Single Oral Dose 40mg PRAX-628 tablet then 4x10mg PRAX-628 capsules

    40 mg PRAX-628 tablet followed by 4×10 mg PRAX-628 capsules administered orally.

    Drug: PRAX-628

  • Experimental
    Single Oral Dose 4x10mg PRAX-628 capsules then 40mg PRAX-628 tablet

    4×10 mg PRAX-628 capsules followed by 40 mg PRAX-628 tablet administered orally.

    Drug: PRAX-628

Interventions

  • DrugPRAX-628

    Once daily oral

06

What researchers measure

Primary outcomes

  1. To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules

    Geometric mean ratio (90% CI) for maximum observed plasma concentration (Cmax)

    Time frame: 28 days

  2. To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules

    Area under the plasma concentration time curve from time zero to infinity (AUCinf) of a single dose of PRAX-628 40 mg tablet (test), and the same dose delivered with PRAX-628 10 mg capsules (reference)

    Time frame: 28 days

Secondary outcomes

  1. To evaluate the pharmacokinetics (PK) of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Plasma concentrations of PRAX-628 (Cmax)

    Time frame: 28 days

  2. To evaluate the pharmacokinetics (PK) of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Time to maximum plasma drug concentration (tmax)

    Time frame: 28 days

  3. To evaluate the pharmacokinetics (PK) of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 28 days

  4. To evaluate the safety and tolerability of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Incidence and severity of adverse events (AEs)

    Time frame: 32 days

  5. To evaluate the safety and tolerability of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Change in tympanic temperature in Celsius

    Time frame: 32 days

  6. To evaluate the safety and tolerability of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Change in heart rate in beats per minute

    Time frame: 32 days

  7. To evaluate the safety and tolerability of single 40 mg oral doses of PRAX-628 tablet and PRAX-628 capsules

    Change in blood pressure in mm/Hg

    Time frame: 32 days

  8. To evaluate the safety and tolerability of single 40 mg oral doses of PRAX-628 tablet and PRAX 628 capsules

    Change in respiratory rate in breaths per minute

    Time frame: 32 days

  9. Number of Participants With Clinically Significant Changes in Chemistry parameters

    The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.

    Time frame: 32 days

  10. Number of Participants With Clinically Significant Changes in Hematology parameters

    The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.

    Time frame: 32 days

  11. Number of Participants With Clinically Significant Changes in Urinalysis

    The Princpal investigatort (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.

    Time frame: 32 days

07

Study locations

1 site
  • Nucleus Network Melbourne
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 21, 2025
StartActual
Apr 28, 2025
Primary completionActual
Jun 5, 2025
CompletionActual
Jun 5, 2025
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06840925
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Apr 28, 2025
Primary completion
Jun 5, 2025
Completion
Jun 5, 2025
Last update
Aug 3, 2026

Study contacts

Director, Clinical Development
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion